ClinicalTrials.gg
CompletedNCT05456529Updated Jun 25, 2025Results posted

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

A Phase 3 interventional study of Ruxolitinib Cream in Atopic Dermatitis (AD), sponsored by Incyte Corporation. Completed at 38 sites in 3 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
103
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.

Enrollment
7th of 15
103 · median 77
Started
2022
the only one that year
Phase 3
6 of 15
none open now
Registered
10th of 15
by date
Lead sponsor
13 of 15
Incyte Corporation

Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 7th largest by enrollment, is the only one that started in 2022, is one of 6 in phase 3, and was the 10th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ruxolitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).

Read the detailed description

The study comprises of a 8 week continuous treatment period followed by 44 week Long Term Safety (LTS) period and 30 days safety follow up period. During Continuous treatment period all lesions identified at baseline will be treated and during LTS period only active lesions will be treated.

03

Conditions studied

  • Atopic Dermatitis (AD)

Keywords

  • atopic dermatitis (AD)
  • adolescents
  • pruritus
  • eczema
  • topical therapy
  • JAK inhibitor
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of Atopic Dermatitis (AD) as defined by the Hanifin and Rajka (1980) criteria.
  • Duration of AD of at least 2 years.
  • Total IGA score of 2 to 3 at the screening and baseline visits.
  • Percent BSA (excluding the scalp) with AD involvement of 3% to 20% at the screening and baseline visits.
  • Atopic dermatitis not adequately controlled with other topical prescription therapies or when those therapies are not advisable.
  • Agree to discontinue all agents used to treat AD from screening through the final follow up visit.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • An unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to baseline.
  • Concurrent conditions and history of other diseases
  • Any current and/or history of serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including application of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data. For example:
  • or uncontrolled cardiovascular disease, including unstable angina, acute myocardial infarction or stroke within 6 months from Day 1 of study cream application, Class III or IV congestive heart failure, and arrhythmia requiring therapy or uncontrolled hypertension (blood pressure > 150/90 mm Hg) unless approved by the medical monitor/sponsor.
  • Current and/or history of in the 5 years preceding the baseline visit, except for adequately treated, nonmetastatic nonmelanoma skin cancer.
  • Current and/or history of arterial or venous thrombosis, including DVT and PE.
  • Current and/or history of active tuberculosis or current and/or history of latent tuberculosis unless adequately treated.
  • Any of the following clinical laboratory test results at screening:

    1. \< 100 g/L (\< 10 g/dL)
    2. Liver function tests:
  • or ALT ≥ 2.5 ×
  • Total > 1.5 × ULN with the exception of Gilbert disease. c. Estimated \< 30 mL/min/1.73 m2 (using the CKD Epidemiology Collaboration equation).

    d. Positive serology test results for antibody. e. Any other clinically significant laboratory result that, in the opinion of the investigator, poses a significant risk to the participant.

  • Use of any of the following treatments within the indicated before baseline:

    1. 5 half-lives or 12 weeks, whichever is longer - biologic agents (eg, dupilumab).
    2. 4 weeks - systemic or adrenocorticotropic hormone analogues, cyclosporine, methotrexate, azathioprine, or other systemic or immunomodulating agents (eg, mycophenolate or tacrolimus).
    3. 2 weeks - immunizations with ; sedating antihistamines, unless on long-term stable regimen (nonsedating antihistamines are permitted).

      Note: Live-attenuated vaccines are not recommended during the CT period. Note: COVID-19 vaccination is allowed.

    4. 1 week - use of other topical treatments for AD (other than bland emollients, eg, Aveeno® creams, ointments, sprays, soap substitutes), such as topical antipruritics (eg, doxepin cream), corticosteroids, calcineurin inhibitors, PDE4 inhibitors, coal tar (shampoo), antibiotics, or antibacterial cleansing body wash/soap.

Note: Diluted sodium hypochlorite "bleach" baths are allowed as long as they do not exceed 2 baths per week and their frequency remains the same throughout the study.

  • Previously received systemic or topical JAK inhibitors (eg, ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).
  • Ultraviolet light therapy or prolonged exposure to natural or artificial sources of UV radiation (eg, sunlight or tanning booth) within 2 weeks prior to the baseline visit and/or intention to have such exposure during the study, which is thought by the investigator to potentially impact the participant's AD.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before baseline with another medication or current enrollment in another investigational drug protocol.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before baseline with a strong inhibitor.
  • Inability to draw blood for PK analysis from any nonlesional areas.
  • Known allergy or reaction to any component of the study cream formulation.
  • In the opinion of the investigator unable or unlikely to comply with the administration schedule and study evaluations.

Further exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Ruxolitinib

    Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.

    Drug: Ruxolitinib Cream

Interventions

  • Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.

    Also known as: INCB18424 cream

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and up to 30 days after the last application of study cream.

    Time frame: up to 462 days

  2. Number of Participants With ≥Grade 3 TEAEs

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and up to 30 days after the last application of study cream. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to 462 days

Secondary outcomes

  1. CT Period: Number of Participants With a Worst Abnormal Post-Baseline Basophil, Eosinophil, Leukocyte, Lymphocyte, Monocyte, Neutrophil, and Platelet Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils, and platelets were measured in 10\^9 cells per liter.

    Time frame: up to Week 8

  2. CT Period: Number of Participants With a Worst Abnormal Post-Baseline Baso/Leuko, Eosino/Leuko, Lymphocyte/Leuko, Monocyte/Leuko, and Neutro/Leuko Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils (baso)/leukocytes (leuk), eosinophils (eosino)/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes, and neutrophils (neutro)/leukocytes were measured as a percentage.

    Time frame: up to Week 8

  3. CT Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Mean Corpuscular Volume and Mean Platelet Volume Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocyte mean corpuscular volume and mean platelet volume were measured in femtoliters.

    Time frame: up to Week 8

  4. CT Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocytes were measured in 10\^12/Liter.

    Time frame: up to Week 8

  5. CT Period: Number of Participants With a Worst Abnormal Post-Baseline Hematocrit Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hematocrit was measured in liters of red blood cells per liter of blood (L/L).

    Time frame: up to Week 8

  6. CT Period: Number of Participants With a Worst Abnormal Post-Baseline Hemoglobin Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hemoglobin was measured in grams per liter.

    Time frame: up to Week 8

  7. LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Basophil, Eosinophil, Leukocyte, Lymphocyte, Monocyte, Neutrophil, and Platelet Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils, and platelets were measured in 10\^9 cells per liter.

    Time frame: from Week 9 up to Week 52 (44 weeks)

  8. LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Baso/Leuko, Eosino/Leuko, Lymphocyte/Leuko, Monocyte/Leuko, and Neutro/Leuko Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils (baso)/leukocytes (leuko), eosinophils (eosino)/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes, and neutrophils (neutro)/leukocytes were measured as a percentage.

    Time frame: from Week 9 up to Week 52 (44 weeks)

  9. LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Mean Corpuscular Volume and Mean Platelet Volume Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocyte mean corpuscular volume and mean platelet volume were measured in femtoliters.

    Time frame: from Week 9 up to Week 52 (44 weeks)

  10. LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocytes were measured in 10\^12/Liter.

    Time frame: from Week 9 up to Week 52 (44 weeks)

  11. LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Hematocrit Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hematocrit was measured in liters of red blood cells per liter of blood (L/L).

    Time frame: from Week 9 up to Week 52 (44 weeks)

  12. LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Hemoglobin Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hemoglobin was measured in grams per liter.

    Time frame: from Week 9 up to Week 52 (44 weeks)

  13. CT Period: Number of Participants With a Worst Abnormal Post-Baseline ALT, ALP, AST, CL, and LDH Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) were measured in units per liter.

    Time frame: up to Week 8

  14. CT Period: Number of Participants With a Worst Abnormal Post-Baseline Albumin Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Albumin was measured in grams per liter.

    Time frame: up to Week 8

  15. CT Period: Number of Participants With a Worst Abnormal Post-Baseline Bilirubin, Creatinine, and Direct Bilirubin Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Bilirubin, creatinine, and direct bilirubin were measured in micromoles per liter (µmol/L).

    Time frame: up to Week 8

  16. CT Period: Number of Participants With a Worst Abnormal Post-Baseline Calcium, Chloride, Glucose, Phosphate, Potassium, Sodium, and Urea Nitrogen Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Calcium, chloride, glucose, phosphate, potassium, sodium, and urea nitrogen were measured in millimoles per liter (mmol/L).

    Time frame: up to Week 8

  17. CT Period: Number of Participants With a Worst Abnormal Post-Baseline Creatinine Clearance Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Creatinine clearance was measured in milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m\^2).

    Time frame: up to Week 8

  18. LTS Period: Number of Participants With a Worst Abnormal Post-Baseline ALT, ALP, AST, CL, and LDH Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. ALT, ALP, AST, CK, and LDH were measured in units per liter.

    Time frame: from Week 9 up to Week 52 (44 weeks)

  19. LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Albumin Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Albumin was measured in grams per liter.

    Time frame: from Week 9 up to Week 52 (44 weeks)

  20. LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Bilirubin, Creatinine, and Direct Bilirubin Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Bilirubin, creatinine, and direct bilirubin were measured in micromoles per liter (µmol/L).

    Time frame: from Week 9 up to Week 52 (44 weeks)

  21. LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Calcium, Chloride, Glucose, Phosphate, Potassium, Sodium, and Urea Nitrogen Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Calcium, chloride, glucose, phosphate, potassium, sodium, and urea nitrogen were measured in millimoles per liter (mmol/L).

    Time frame: from Week 9 up to Week 52 (44 weeks)

  22. LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Creatinine Clearance Value of Low, Normal, High, Low and High, and Missing

    Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Creatinine clearance was measured in milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m\^2).

    Time frame: from Week 9 up to Week 52 (44 weeks)

  23. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 8, 44, and 52

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 8, 44, and 52

  24. Change From Baseline in Pulse at Weeks 8, 44, and 52

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 8, 44, and 52

  25. Change From Baseline in Respiration Rate at Weeks 8, 44, and 52

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 8, 44, and 52

  26. Change From Baseline in Body Temperature at Weeks 8, 44, and 52

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 8, 44, and 52

  27. Change From Baseline in Height at Weeks 8 and 52

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 8 and 52

  28. Change From Baseline in Weight at Weeks 8 and 52

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 8 and 52

  29. Plasma Concentration of Ruxolitinib

    Blood samples were drawn to assess plasma concentration.

    Time frame: prior to study cream application at Weeks 2 and 4

07

Results

Posted Jun 25, 2025

Participant flow

8-week Continuous Treatment (CT) Period
Participant flow — 8-week Continuous Treatment (CT) Period
MilestoneRuxolitinib 1.5% Cream BID
Started103
Completed92
Not completed11
Withdrew: Lost to follow-up5
Withdrew: Lack of efficacy2
Withdrew: Protocol-specified withdrawal criterion met1
Withdrew: Withdrawal by subject3
44-week Long-term Safety Period
Participant flow — 44-week Long-term Safety Period
MilestoneRuxolitinib 1.5% Cream BID
Started92
Completed61
Not completed31
Withdrew: Lost to follow-up12
Withdrew: Lack of efficacy1
Withdrew: Physician decision2
Withdrew: Protocol-specified withdrawal criterion met1
Withdrew: Withdrawal by subject12
Withdrew: Withdrawal by sponsor2
Withdrew: Unable to attend the follow-up visit1

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and up to 30 days after the last application of study cream.

Time frame:
up to 462 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsRuxolitinib 1.5% Cream BID
Number of Participants With Treatment-emergent Adverse Events (TEAEs)42
PrimaryNumber of Participants With ≥Grade 3 TEAEs

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and up to 30 days after the last application of study cream. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to 462 days
Reported as:
Count of participants · Participants
Number of Participants With ≥Grade 3 TEAEs
ParticipantsRuxolitinib 1.5% Cream BID
Number of Participants With ≥Grade 3 TEAEs3
SecondaryCT Period: Number of Participants With a Worst Abnormal Post-Baseline Basophil, Eosinophil, Leukocyte, Lymphocyte, Monocyte, Neutrophil, and Platelet Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils, and platelets were measured in 10\^9 cells per liter.

Time frame:
up to Week 8
Reported as:
Count of participants · Participants
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Basophil, Eosinophil, Leukocyte, Lymphocyte, Monocyte, Neutrophil, and Platelet Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Basophils, low0
Basophils, normal94
Basophils, high1
Basophils, low and high0
Basophils, missing8
Eosinophils, low0
Eosinophils, normal83
Eosinophils, high19
Eosinophils, low and high0
Eosinophils, missing1
Leukocytes, low18
Leukocytes, normal83
Leukocytes, high1
Leukocytes, low and high0
Leukocytes, missing1
Lymphocytes, low7
Lymphocytes, normal95
Lymphocytes, high0
Lymphocytes, low and high0
Lymphocytes, missing1
Monocytes, low0
Monocytes, normal92
Monocytes, high10
Monocytes, low and high0
Monocytes, missing1
Neutrophils, low13
Neutrophils, normal87
Neutrophils, high2
Neutrophils, low and high0
Neutrophils, missing1
Platelets, low5
Platelets, normal75
Platelets, high21
Platelets, low and high1
Platelets, missing1
SecondaryCT Period: Number of Participants With a Worst Abnormal Post-Baseline Baso/Leuko, Eosino/Leuko, Lymphocyte/Leuko, Monocyte/Leuko, and Neutro/Leuko Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils (baso)/leukocytes (leuk), eosinophils (eosino)/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes, and neutrophils (neutro)/leukocytes were measured as a percentage.

Time frame:
up to Week 8
Reported as:
Count of participants · Participants
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Baso/Leuko, Eosino/Leuko, Lymphocyte/Leuko, Monocyte/Leuko, and Neutro/Leuko Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Basophils/leukocytes, low0
Basophils/leukocytes, normal84
Basophils/leukocytes, high18
Basophils/leukocytes, low and high0
Basophils/leukocytes, missing1
Eosinophils/leukocytes, low0
Eosinophils/leukocytes, normal73
Eosinophils/leukocytes, high29
Eosinophils/leukocytes, low and high0
Eosinophils/leukocytes, missing1
Lymphocytes/leukocytes, low29
Lymphocytes/leukocytes, normal47
Lymphocytes/leukocytes, high22
Lymphocytes/leukocytes, low and high4
Lymphocytes/leukocytes, missing1
Monocytes/leukocytes, low3
Monocytes/leukocytes, normal94
Monocytes/leukocytes, high5
Monocytes/leukocytes, low and high0
Monocytes/leukocytes, missing1
Neutrophils/leukocytes, low6
Neutrophils/leukocytes, normal66
Neutrophils/leukocytes, high30
Neutrophils/leukocytes, low and high0
Neutrophils/leukocytes, missing1
SecondaryCT Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Mean Corpuscular Volume and Mean Platelet Volume Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocyte mean corpuscular volume and mean platelet volume were measured in femtoliters.

Time frame:
up to Week 8
Reported as:
Count of participants · Participants
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Mean Corpuscular Volume and Mean Platelet Volume Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Erythrocyte mean corpuscular volume, low3
Erythrocyte mean corpuscular volume, normal88
Erythrocyte mean corpuscular volume, high11
Erythrocyte mean corpuscular volume, low and high0
Erythrocyte mean corpuscular volume, missing1
Mean platelet volume, low5
Mean platelet volume, normal97
Mean platelet volume, high0
Mean platelet volume, low and high0
Mean platelet volume, missing1
SecondaryCT Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocytes were measured in 10\^12/Liter.

Time frame:
up to Week 8
Reported as:
Count of participants · Participants
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Low14
Normal66
High22
Low and high0
Missing1
SecondaryCT Period: Number of Participants With a Worst Abnormal Post-Baseline Hematocrit Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hematocrit was measured in liters of red blood cells per liter of blood (L/L).

Time frame:
up to Week 8
Reported as:
Count of participants · Participants
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Hematocrit Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Low2
Normal88
High12
Low and high0
Missing1
SecondaryCT Period: Number of Participants With a Worst Abnormal Post-Baseline Hemoglobin Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hemoglobin was measured in grams per liter.

Time frame:
up to Week 8
Reported as:
Count of participants · Participants
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Hemoglobin Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Low19
Normal79
High4
Low and high0
Missing1
SecondaryLTS Period: Number of Participants With a Worst Abnormal Post-Baseline Basophil, Eosinophil, Leukocyte, Lymphocyte, Monocyte, Neutrophil, and Platelet Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils, and platelets were measured in 10\^9 cells per liter.

Time frame:
from Week 9 up to Week 52 (44 weeks)
Reported as:
Count of participants · Participants
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Basophil, Eosinophil, Leukocyte, Lymphocyte, Monocyte, Neutrophil, and Platelet Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Basophils, low0
Basophils, normal85
Basophils, high2
Basophils, low and high0
Basophils, missing5
Eosinophils, low0
Eosinophils, normal63
Eosinophils, high25
Eosinophils, low and high0
Eosinophils, missing4
Leukocytes, low20
Leukocytes, normal62
Leukocytes, high6
Leukocytes, low and high0
Leukocytes, missing4
Lymphocytes, low5
Lymphocytes, normal82
Lymphocytes, high1
Lymphocytes, low and high0
Lymphocytes, missing4
Monocytes, low0
Monocytes, normal75
Monocytes, high13
Monocytes, low and high0
Monocytes, missing4
Neutrophils, low12
Neutrophils, normal66
Neutrophils, high10
Neutrophils, low and high0
Neutrophils, missing4
Platelets, low3
Platelets, normal60
Platelets, high25
Platelets, low and high0
Platelets, missing4
SecondaryLTS Period: Number of Participants With a Worst Abnormal Post-Baseline Baso/Leuko, Eosino/Leuko, Lymphocyte/Leuko, Monocyte/Leuko, and Neutro/Leuko Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils (baso)/leukocytes (leuko), eosinophils (eosino)/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes, and neutrophils (neutro)/leukocytes were measured as a percentage.

Time frame:
from Week 9 up to Week 52 (44 weeks)
Reported as:
Count of participants · Participants
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Baso/Leuko, Eosino/Leuko, Lymphocyte/Leuko, Monocyte/Leuko, and Neutro/Leuko Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Basophils/leukocytes, low0
Basophils/leukocytes, normal67
Basophils/leukocytes, high21
Basophils/leukocytes, low and high0
Basophils/leukocytes, missing4
Eosinophils/leukocytes, low0
Eosinophils/leukocytes, normal49
Eosinophils/leukocytes, high39
Eosinophils/leukocytes, low and high0
Eosinophils/leukocytes, missing4
Lymphocytes/leukocytes, low39
Lymphocytes/leukocytes, normal29
Lymphocytes/leukocytes, high18
Lymphocytes/leukocytes, low and high2
Lymphocytes/leukocytes, missing4
Monocytes/leukocytes, low13
Monocytes/leukocytes, normal68
Monocytes/leukocytes, high7
Monocytes/leukocytes, low and high0
Monocytes/leukocytes, missing4
Neutrophils/leukocytes, low8
Neutrophils/leukocytes, normal43
Neutrophils/leukocytes, high37
Neutrophils/leukocytes, low and high0
Neutrophils/leukocytes, missing4
SecondaryLTS Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Mean Corpuscular Volume and Mean Platelet Volume Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocyte mean corpuscular volume and mean platelet volume were measured in femtoliters.

Time frame:
from Week 9 up to Week 52 (44 weeks)
Reported as:
Count of participants · Participants
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Mean Corpuscular Volume and Mean Platelet Volume Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Erythrocyte mean corpuscular volume, low4
Erythrocyte mean corpuscular volume, normal56
Erythrocyte mean corpuscular volume, high28
Erythrocyte mean corpuscular volume, low and high0
Erythrocyte mean corpuscular volume, missing4
Mean platelet volume, low11
Mean platelet volume, normal77
Mean platelet volume, high0
Mean platelet volume, low and high0
Mean platelet volume, missing4
SecondaryLTS Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocytes were measured in 10\^12/Liter.

Time frame:
from Week 9 up to Week 52 (44 weeks)
Reported as:
Count of participants · Participants
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Low19
Normal42
High26
Low and high1
Missing4
SecondaryLTS Period: Number of Participants With a Worst Abnormal Post-Baseline Hematocrit Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hematocrit was measured in liters of red blood cells per liter of blood (L/L).

Time frame:
from Week 9 up to Week 52 (44 weeks)
Reported as:
Count of participants · Participants
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Hematocrit Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Low2
Normal49
High37
Low and high0
Missing4
SecondaryLTS Period: Number of Participants With a Worst Abnormal Post-Baseline Hemoglobin Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hemoglobin was measured in grams per liter.

Time frame:
from Week 9 up to Week 52 (44 weeks)
Reported as:
Count of participants · Participants
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Hemoglobin Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Low26
Normal55
High7
Low and high0
Missing4
SecondaryCT Period: Number of Participants With a Worst Abnormal Post-Baseline ALT, ALP, AST, CL, and LDH Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) were measured in units per liter.

Time frame:
up to Week 8
Reported as:
Count of participants · Participants
CT Period: Number of Participants With a Worst Abnormal Post-Baseline ALT, ALP, AST, CL, and LDH Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
ALT, low0
ALT, normal100
ALT, high3
ALT, low and high0
ALT, missing0
ALP, low14
ALP, normal89
ALP, high0
ALP, low and high0
ALP, missing0
AST, low0
AST, normal102
AST, high1
AST, low and high0
AST, missing0
CK, low3
CK, normal77
CK, high22
CK, low and high1
CK, missing0
LDH, low7
LDH, normal91
LDH, high5
LDH, low and high0
LDH, missing0
SecondaryCT Period: Number of Participants With a Worst Abnormal Post-Baseline Albumin Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Albumin was measured in grams per liter.

Time frame:
up to Week 8
Reported as:
Count of participants · Participants
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Albumin Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Low0
Normal23
High80
Low and high0
Missing0
SecondaryCT Period: Number of Participants With a Worst Abnormal Post-Baseline Bilirubin, Creatinine, and Direct Bilirubin Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Bilirubin, creatinine, and direct bilirubin were measured in micromoles per liter (µmol/L).

Time frame:
up to Week 8
Reported as:
Count of participants · Participants
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Bilirubin, Creatinine, and Direct Bilirubin Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Bilirubin, low31
Bilirubin, normal68
Bilirubin, high4
Bilirubin, low and high0
Bilirubin, missing0
Creatinine, low54
Creatinine, normal49
Creatinine, high0
Creatinine, low and high0
Creatinine, missing0
Direct bilirubin, low0
Direct bilirubin, normal4
Direct bilirubin, high0
Direct bilirubin, low and high0
Direct bilirubin, missing99
SecondaryCT Period: Number of Participants With a Worst Abnormal Post-Baseline Calcium, Chloride, Glucose, Phosphate, Potassium, Sodium, and Urea Nitrogen Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Calcium, chloride, glucose, phosphate, potassium, sodium, and urea nitrogen were measured in millimoles per liter (mmol/L).

Time frame:
up to Week 8
Reported as:
Count of participants · Participants
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Calcium, Chloride, Glucose, Phosphate, Potassium, Sodium, and Urea Nitrogen Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Calcium, low0
Calcium, normal84
Calcium, high19
Calcium, low and high0
Calcium, missing0
Chloride, low52
Chloride, normal51
Chloride, high0
Chloride, low and high0
Chloride, missing0
Glucose, low13
Glucose, normal86
Glucose, high4
Glucose, low and high0
Glucose, missing0
Phosphate, low0
Phosphate, normal82
Phosphate, high21
Phosphate, low and high0
Phosphate, missing0
Potassium, low0
Potassium, normal80
Potassium, high23
Potassium, low and high0
Potassium, missing0
Sodium, low8
Sodium, normal93
Sodium, high1
Sodium, low and high1
Sodium, missing0
Urea nitrogen, low2
Urea nitrogen, normal86
Urea nitrogen, high15
Urea nitrogen, low and high0
Urea nitrogen, missing0
SecondaryCT Period: Number of Participants With a Worst Abnormal Post-Baseline Creatinine Clearance Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Creatinine clearance was measured in milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m\^2).

Time frame:
up to Week 8
Reported as:
Count of participants · Participants
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Creatinine Clearance Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Low0
Normal2
High4
Low and high0
Missing97
SecondaryLTS Period: Number of Participants With a Worst Abnormal Post-Baseline ALT, ALP, AST, CL, and LDH Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. ALT, ALP, AST, CK, and LDH were measured in units per liter.

Time frame:
from Week 9 up to Week 52 (44 weeks)
Reported as:
Count of participants · Participants
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline ALT, ALP, AST, CL, and LDH Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
ALT, low5
ALT, normal78
ALT, high5
ALT, low and high0
ALT, missing4
ALP, low14
ALP, normal69
ALP, high5
ALP, low and high0
ALP, missing4
AST, low2
AST, normal82
AST, high4
AST, low and high0
AST, missing4
CK, low5
CK, normal56
CK, high27
CK, low and high0
CK, missing4
LDH, low9
LDH, normal72
LDH, high7
LDH, low and high0
LDH, missing4
SecondaryLTS Period: Number of Participants With a Worst Abnormal Post-Baseline Albumin Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Albumin was measured in grams per liter.

Time frame:
from Week 9 up to Week 52 (44 weeks)
Reported as:
Count of participants · Participants
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Albumin Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Low0
Normal19
High69
Low and high0
Missing4
SecondaryLTS Period: Number of Participants With a Worst Abnormal Post-Baseline Bilirubin, Creatinine, and Direct Bilirubin Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Bilirubin, creatinine, and direct bilirubin were measured in micromoles per liter (µmol/L).

Time frame:
from Week 9 up to Week 52 (44 weeks)
Reported as:
Count of participants · Participants
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Bilirubin, Creatinine, and Direct Bilirubin Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Bilirubin, low40
Bilirubin, normal43
Bilirubin, high5
Bilirubin, low and high0
Bilirubin, missing4
Creatinine, low58
Creatinine, normal30
Creatinine, high0
Creatinine, low and high0
Creatinine, missing4
Direct bilirubin, low0
Direct bilirubin, normal4
Direct bilirubin, high0
Direct bilirubin, low and high0
Direct bilirubin, missing88
SecondaryLTS Period: Number of Participants With a Worst Abnormal Post-Baseline Calcium, Chloride, Glucose, Phosphate, Potassium, Sodium, and Urea Nitrogen Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Calcium, chloride, glucose, phosphate, potassium, sodium, and urea nitrogen were measured in millimoles per liter (mmol/L).

Time frame:
from Week 9 up to Week 52 (44 weeks)
Reported as:
Count of participants · Participants
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Calcium, Chloride, Glucose, Phosphate, Potassium, Sodium, and Urea Nitrogen Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Calcium, low2
Calcium, normal72
Calcium, high14
Calcium, low and high0
Calcium, missing4
Chloride, low54
Chloride, normal34
Chloride, high0
Chloride, low and high0
Chloride, missing4
Glucose, low12
Glucose, normal72
Glucose, high4
Glucose, low and high0
Glucose, missing4
Phosphate, low1
Phosphate, normal62
Phosphate, high25
Phosphate, low and high0
Phosphate, missing4
Potassium, low1
Potassium, normal66
Potassium, high21
Potassium, low and high0
Potassium, missing4
Sodium, low17
Sodium, normal70
Sodium, high0
Sodium, low and high1
Sodium, missing4
Urea nitrogen, low4
Urea nitrogen, normal65
Urea nitrogen, high19
Urea nitrogen, low and high0
Urea nitrogen, missing4
SecondaryLTS Period: Number of Participants With a Worst Abnormal Post-Baseline Creatinine Clearance Value of Low, Normal, High, Low and High, and Missing

Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Creatinine clearance was measured in milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m\^2).

Time frame:
from Week 9 up to Week 52 (44 weeks)
Reported as:
Count of participants · Participants
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Creatinine Clearance Value of Low, Normal, High, Low and High, and Missing
ParticipantsRuxolitinib 1.5% Cream BID
Low0
Normal10
High11
Low and high0
Missing71
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 8, 44, and 52

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 8, 44, and 52
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 8, 44, and 52
millimeters of mercury (mmHg)Ruxolitinib 1.5% Cream BID
Baseline, SBP112.7 ± 11.14
Change from Baseline at Week 8, SBP0.6 ± 10.01
Change from Baseline at Week 44, SBP-1.4 ± 11.10
Change from Baseline at Week 52, SBP1.0 ± 10.77
Baseline, DBP71.0 ± 8.03
Change from Baseline at Week 8, DBP0.2 ± 8.35
Change from Baseline at Week 44, DBP0.1 ± 9.31
Change from Baseline at Week 52, DBP1.0 ± 8.04
SecondaryChange From Baseline in Pulse at Weeks 8, 44, and 52

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 8, 44, and 52
Reported as:
Mean · beats per minute
Change From Baseline in Pulse at Weeks 8, 44, and 52
beats per minuteRuxolitinib 1.5% Cream BID
Baseline78.8 ± 12.71
Change from Baseline at Week 80.5 ± 11.23
Change from Baseline at Week 44-0.6 ± 11.69
Change from Baseline at Week 52-0.4 ± 12.18
SecondaryChange From Baseline in Respiration Rate at Weeks 8, 44, and 52

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 8, 44, and 52
Reported as:
Mean · breaths per minute
Change From Baseline in Respiration Rate at Weeks 8, 44, and 52
breaths per minuteRuxolitinib 1.5% Cream BID
Baseline16.1 ± 2.50
Change from Baseline at Week 80.7 ± 6.91
Change from Baseline at Week 44-0.5 ± 1.91
Change from Baseline at Week 52-0.1 ± 1.88
SecondaryChange From Baseline in Body Temperature at Weeks 8, 44, and 52

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 8, 44, and 52
Reported as:
Mean · degrees Celsius
Change From Baseline in Body Temperature at Weeks 8, 44, and 52
degrees CelsiusRuxolitinib 1.5% Cream BID
Baseline36.5 ± 0.42
Change from Baseline at Week 80.0 ± 0.40
Change from Baseline at Week 440.1 ± 0.43
Change from Baseline at Week 520.1 ± 0.44
SecondaryChange From Baseline in Height at Weeks 8 and 52

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 8 and 52
Reported as:
Mean · centimeters
Change From Baseline in Height at Weeks 8 and 52
centimetersRuxolitinib 1.5% Cream BID
Baseline165.1 ± 9.88
Change from Baseline at Week 80.7 ± 1.20
Change from Baseline at Week 523.1 ± 3.31
SecondaryChange From Baseline in Weight at Weeks 8 and 52

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 8 and 52
Reported as:
Mean · kilograms
Change From Baseline in Weight at Weeks 8 and 52
kilogramsRuxolitinib 1.5% Cream BID
Baseline65.0 ± 18.25
Change from Baseline at Week 80.9 ± 3.11
Change from Baseline at Week 523.8 ± 7.01
SecondaryPlasma Concentration of Ruxolitinib

Blood samples were drawn to assess plasma concentration.

Time frame:
prior to study cream application at Weeks 2 and 4
Reported as:
Mean · nanomoles per liter (nM)
Plasma Concentration of Ruxolitinib
nanomoles per liter (nM)Ruxolitinib 1.5% Cream BID
Week 221.4 ± 27.7
Week 424.6 ± 38.2

Adverse events

Collected over from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to approximately 20 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib 1.5% Cream BID0/103 (0%)2/103 (1.9%)20/103 (19.4%)
Most frequent serious events
Most frequent serious events
EventRuxolitinib 1.5% Cream BID
DepressionPsychiatric disorders1/103
Pneumonia mycoplasmalInfections and infestations1/103
Most frequent other events
Most frequent other events
EventRuxolitinib 1.5% Cream BID
Upper respiratory tract infectionInfections and infestations11/103
NasopharyngitisInfections and infestations9/103

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ruxolitinib 1.5% Cream BID
Mean14.3 ± 1.64
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib 1.5% Cream BID
Female56
Male47
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ruxolitinib 1.5% Cream BID
Hispanic or Latino23
Not Hispanic or Latino80
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ruxolitinib 1.5% Cream BID
White/Caucasian46
Black/African-American31
Asian18
Native Hawaiian/Pacific Islander2
Unknown1
Asian/White1
Middle Eastern (Arab)1
East Indian1
White/Black1
Asian, Dominican, Cuban1
08

Study locations

38 sites
  • Arkansas Research Trials
    North Little Rock, Arkansas 72117, United States
  • First Oc Dermatology
    Fountain Valley, California 92708, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Peninsula Research Associates Pra
    Rolling Hills Estates, California 90274, United States
  • Advanced Rx Clinical Research Group, Inc
    Westminster, California 92683-4567, United States
  • Encore Medical Research, Llc Hollywood
    Hollywood, Florida 33021, United States
  • Solutions Through Advanced Research, Inc
    Jacksonville, Florida 32256, United States
  • Acevedo Clinical Research
    Miami, Florida 33142-2946, United States
  • Skin Research of South Florida, Llc
    Miami, Florida 33173, United States
  • Well Pharma Medical Research Corp.
    Miami, Florida 33173, United States
  • Forward Clinical Trials
    Tampa, Florida 33613, United States
  • Iact Health
    Columbus, Georgia 31904, United States
  • Sneeze Wheeze and Itch Associates Llc
    Normal, Illinois 61761-6280, United States
  • Northshore University Health System
    Skokie, Illinois 60077, United States
  • Meridian Clinical Research
    Baton Rouge, Louisiana 70808, United States
  • Skin Specialists Pc the Advanced Skin Research Center
    Omaha, Nebraska 68144, United States
  • Empire Dermatology
    East Syracuse, New York 13057, United States
  • Sadick Dermatology Sadick Research Group
    New York, New York 10075, United States
  • Ohio Pediatric Research Association
    Dayton, Ohio 45414, United States
  • Aventiv Research Inc-Dublin
    Dublin, Ohio 43016, United States
  • Apex Clinical Research Center
    Mayfield Heights, Ohio 44124, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • International Clinical Research Tennessee Llc
    Murfreesboro, Tennessee 37130, United States
  • Arlington Research Center
    Arlington, Texas 76011, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Jordan Valley Medical Center
    West Jordan, Utah 84088-8873, United States
  • Dermatology Research Institute
    Calgary, Alberta T1Y 0B4, Canada
  • Dr. Chih-Ho Hong Medical Inc.
    Surrey, British Columbia V3R 6A7, Canada
  • Lmc Manna Research (London)
    London, Ontario N6A 2C2, Canada
  • Manna Research Toronto
    Toronto, Ontario M9W 4L6, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Xlr8 Medical Research
    Windsor, Ontario N8W 1E6, Canada
  • Centrum Medyczne Pratia Czestochowa
    Częstochowa, 42-200, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, 40-611, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1
    Lublin, 20-081, Poland
  • Dermedic Dr. Zdybski
    Ostrowiec Świętokrzyski, 27-400, Poland
  • Centrum Medyczne Evimed
    Warsaw, 02-625, Poland
  • Klinika Ambroziak
    Warsaw, 02-953, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in May 2024, 20 months.

Results were first posted in Jun 2025, 1 year 1 month after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 20 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2022
First posted
Jul 13, 2022
StartActual
Sep 1, 2022
Primary completionActual
May 17, 2024
CompletionActual
May 17, 2024
Results first posted
Jun 25, 2025
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05456529
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jul 13, 2022
Start date
Sep 1, 2022
Primary completion
May 17, 2024
Completion
May 17, 2024
Results posted
Jun 25, 2025
Last update
Jun 25, 2025

Study contacts

Brett Angel, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion